IP Library Granted Patent US 8,268,240
Granted Patent B2
US 8,268,240 · App. 12/461,647 · Granted Sep 18, 2012

Ciclesonide-containing sterile aqueous suspension

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,268,240
App. No.
12/461,647
Granted
Sep 18, 2012
Kind
B2
Abstract

The present invention provides methods of manufacturing a sterile ciclesonide-containing aqueous suspension comprising the step of sterilization by autoclaving a ciclesonide-containing aqueous suspension.

Claims (10)

1. A method of manufacturing a sterile ciclesonide-containing aqueous suspension comprising the step of sterilization by autoclaving a ciclesonide-containing aqueous suspension.

2. The method of manufacturing a sterile ciclesonide-containing aqueous suspension according to claim 1 , wherein the concentration of ciclesonide after autoclaving is 95% or more compared to that before autoclaving.

3. The method of manufacturing a sterile ciclesonide-containing aqueous suspension according to claim 1 wherein the ciclesonide-containing aqueous suspension additionally contains hydroxypropylmethylcellulose.

4. The method of manufacturing a sterile ciclesonide-containing aqueous suspension according to claim 3 , wherein the hydroxypropylmethylcellulose is hydroxypropylmethylcellulose 2910.

5. The method of manufacturing a sterile ciclesonide-containing aqueous suspension according to claim 2 , wherein the ciclesonide-containing aqueous suspension additionally contains hydroxypropylmethylcellulose.

6. The method of manufacturing a sterile ciclesonide-containing aqueous suspension according to claim 5 , wherein the hydroxypropylmethylcellulose is hydroxypropylmethylcellulose 2910.

7. The method of manufacturing a sterile ciclesonide-containing aqueous suspension according to claim 1 , wherein the autoclaving is carried out at 115° C. for 30 minutes, at 121° C. for 20 minutes, or at 126° C. for 15 minutes.

8. The method of manufacturing a sterile ciclesonide-containing aqueous suspension according to claim 1 , wherein after the sterilization by autoclaving, the ciclesonide-containing sterile aqueous suspension is packaged in a container-closure system that has a structure avoiding contamination of a microorganism.

9. The method of manufacturing a sterile ciclesonide-containing aqueous suspension according to claim 1 , wherein ciclesonide is dispersed in an aqueous medium optionally including hydroxypropylmethylcellulose and a suspending agent prior to autoclaving the ciclesonide-containing aqueous suspension.

10. The method of manufacturing a sterile ciclesonide-containing aqueous suspension according to claim 9 , wherein the ciclesonide-containing aqueous suspension is autoclaved consecutively in a container that is identical to the container wherein the ciclesonide is dispersed in an aqueous medium.

Assignments (17)
RELEASE OF SECURITY INTEREST IN PATENTS Recorded Mar 17, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: COVIS PHARMA GMBH
Reel/Frame 070537/0122 →
RELEASE OF SECURITY INTEREST Recorded Jun 2, 2023
From: BARCLAYS BANK PLC
To: COVIS PHARMA GMBH
Reel/Frame 063841/0208 →
RELEASE OF SECURITY INTEREST Recorded Feb 18, 2022
From: CAPITAL ONE, NATIONAL ASSOCIATION
To: COVIS PHARMA B.V.
Reel/Frame 059043/0239 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (SECOND LIEN) Recorded Feb 18, 2022
From: COVIS PHARMA GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 059232/0514 →
RELEASE OF SECURITY INTEREST Recorded Feb 18, 2022
From: CAPITAL ONE, NATIONAL ASSOCIATION
To: COVIS PHARMA GMBH
Reel/Frame 059043/0226 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY (FIRST LIEN) Recorded Jan 4, 2022
From: COVIS PHARMA GMBH
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 058640/0787 →
SECURITY INTEREST Recorded Feb 22, 2021
From: COVIS PHARMA GMBH
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 055354/0063 →
BUSINESS TRANSFER AND CONTRIBUTION AGREEMENT Recorded Dec 16, 2020
From: COVIS PHARMA B.V.
To: COVIS PHARMA GMBH
Reel/Frame 054793/0416 →
RELEASE OF SECURITY INTEREST Recorded Mar 17, 2020
From: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: COVIS PHARMA B.V.
Reel/Frame 052142/0961 →
SECURITY INTEREST Recorded Mar 12, 2020
From: COVIS PHARMA B.V.
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 052095/0262 →
SECURITY INTEREST Recorded Dec 20, 2018
From: COVIS PHARMA B.V.
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 047834/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2018
From: ASTRAZENECA AB
To: COVIS PHARMA B.V.
Reel/Frame 047761/0435 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2017
From: TAKEDA GMBH
To: ASTRAZENECA AB
Reel/Frame 041328/0362 →
CHANGE OF NAME Recorded Jul 29, 2015
From: NYCOMED GERMANY HOLDING GMBH
To: TAKEDA GMBH
Reel/Frame 036205/0192 →
MERGER Recorded Jul 28, 2015
From: NYCOMED ASSET MANAGEMENT GMBH
To: NYCOMED GERMANY HOLDING GMBH
Reel/Frame 036201/0261 →
MERGER Recorded Jul 28, 2015
From: TAKEDA GMBH
To: NYCOMED ASSET MANAGEMENT GMBH
Reel/Frame 036193/0178 →
CHANGE OF NAME Recorded Mar 21, 2013
From: NYCOMED GMBH
To: TAKEDA GMBH
Reel/Frame 030057/0633 →